about
Plant Alkaloids as Antiplatelet Agent: Drugs of the Future in the Light of Recent DevelopmentsThe safety of clopidogrel.New options with dabigatran etexilate in anticoagulant therapyBalancing antiplatelet and anticoagulant therapies in patients with cardiovascular disease.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.To bleed or not to bleed. Is that the question?Stroke prevention: managing modifiable risk factors.New-onset atrial fibrillation and acute coronary syndrome.Prevention of cardioembolic stroke in patients with atrial fibrillation.Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.Assessment of oral antithrombotic therapy by platelet function testing.Preventing cardioembolic stroke in atrial fibrillation with dabigatran.Hemorrhagic complications in dermatologic surgery.Improving long-term ACS management: is there a role for the new antiplatelets?Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting.A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban.Balancing the risk of complications in foot and ankle surgical patients taking antithrombotic medication.New horizons in platelet research: understanding and harnessing platelet functional diversity.Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis.Cardiac CT and echocardiographic evaluation of peri-device flow after percutaneous left atrial appendage closure using the AMPLATZER cardiac plug device.Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation.Splicing of platelet resident pre-mRNAs upon activation by physiological stimuli results in functionally relevant proteome modifications.Combined low-dose aspirin and warfarin anticoagulant therapy of postoperative atrial fibrillation following mechanical heart valve replacement.Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in Japanese patients.Potentially inappropriate prescribing in Ethiopian geriatric patients hospitalized with cardiovascular disorders using START/STOPP criteria.Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort sMajor bleeding risk associated with warfarin and co-medications in the elderly populationANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndromeLong-term safety of drug-eluting stents in patients on warfarin treatmentIncidence and prognostic implications of late bleeding events after percutaneous mitral valve repair
P2860
Q28076248-1CD8B9BE-B8CC-42A0-9B13-A7D362B1EC36Q33392895-9A12107F-27EC-46F2-9BF3-7C0B96E8DDABQ33888320-060CADFD-2064-487F-AEC0-0C71EFC07E13Q33936118-C0C795CC-008F-45E3-8B89-67D4A429EB54Q34252907-E1870838-9BFE-4AA0-AF27-E4D09D169B0CQ35373575-0FD85A6F-F9A0-40A7-AF3F-307DC1D0500EQ36418118-03C5A726-AE4F-49BD-AA64-F4963FC5D20DQ37770107-38896ECB-20D1-4ECC-BC62-43D5126E5F8CQ37799361-475C5EFE-156B-4636-B98C-15168AABF86CQ37844143-8DD491EA-5E6A-4FA6-9532-46C246264D11Q37902507-E536C6E6-56C2-44B0-9463-924A2F5B1B45Q37940877-A2877F92-C222-490F-A8A3-233C709F3008Q38003714-C82EC5B9-0BB0-4E3B-A215-0B8FE8D98401Q38009041-37C0652F-D68F-4DBB-BDC7-73049C305E14Q38123126-B5C1573F-38ED-4241-B788-DBE3A6456E66Q38167682-4E63A422-689A-4D66-A2F5-7104D1259808Q38233022-190DE2E9-534D-4502-86F9-C9DE61739F66Q38419319-7102588B-9508-4B8C-A188-662E5F88F1E1Q38447545-3733EC52-ED35-4348-A1B2-8E15509C9CE9Q38572789-8B3BE398-A1E3-4833-AF96-C50CD0268AC5Q39131805-6E2E1EAD-E607-4415-B795-522C86AF55F0Q46001195-86E6BAD2-3D06-4514-8862-4CDD50634776Q47660131-84BD48D2-8DB3-460E-BD84-0992915C5AEDQ53080068-0C805375-72C7-455E-9E9F-CB0C28072903Q53151801-363402AF-E564-4D4E-B3F2-D027CB19CFD1Q53686521-F9431877-5D45-4FD3-A28D-743B91FD2B14Q55364273-1B25181E-66D7-41EF-8481-1894311FF698Q57214150-350B7210-10FE-4EEE-BC05-94DC5F41C736Q57764209-8F45B4B7-8A5E-4573-A974-01A35C09E7D1Q57914557-425BF335-12E8-4D53-B933-0834C10F4234Q58718637-98AC0EBA-5558-45C1-BDD9-768778BFA823
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combining antiplatelet and anticoagulant therapies.
@en
Combining antiplatelet and anticoagulant therapies.
@nl
type
label
Combining antiplatelet and anticoagulant therapies.
@en
Combining antiplatelet and anticoagulant therapies.
@nl
prefLabel
Combining antiplatelet and anticoagulant therapies.
@en
Combining antiplatelet and anticoagulant therapies.
@nl
P2093
P1476
Combining antiplatelet and anticoagulant therapies.
@en
P2093
Cindy L Grines
David R Holmes
Dean J Kereiakes
Neal S Kleiman
P304
P356
10.1016/J.JACC.2009.03.044
P407
P577
2009-07-01T00:00:00Z